Central arterial characteristics of gout patients with chronic kidney diseases

International Journal of Rheumatic Diseases

Volumn 20, Issue 5, 2017, Pages 628-638

  Celik, Gulperi ^a   Yilmaz, Sema ^a   Kebapcilar, Levent ^a   Gundogdu, Ali ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

albuminuria; augmentation index; central blood pressures; chronic kidney disease; gout disease

Indexed keywords

ALLOPURINOL; CALCIUM; COLCHICINE; CREATININE; PHOSPHORUS; PREDNISONE; UREA; URIC ACID;

ADULT; AGE; AGED; ARTERIAL STIFFNESS; ARTERIOGRAPHY; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE; BODY MASS; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GOUT; HEART OUTPUT; HEART RATE; HEMATOCRIT; HUMAN; MAINTENANCE THERAPY; MALE; MEAN ARTERIAL PRESSURE; ONSET AGE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PULSE PRESSURE; RENAL SYSTEM PARAMETERS; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; VASCULAR RESISTANCE; ARTERIAL PRESSURE; BRACHIAL ARTERY; CASE CONTROL STUDY; COMPLICATION; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; PULSE WAVE; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARTERIAL PRESSURE; BRACHIAL ARTERY; CARDIAC OUTPUT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GOUT; HEART RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROGNOSIS; PULSE WAVE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR RESISTANCE; VASCULAR STIFFNESS;

EID: 85020522431     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12689     Document Type: Article

References (40)

1. Schreiner O, Wandel E, Himmelsbach GP, Märker-Hermann E (2000) Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for in frequent gout episodes in chronic renal failure patients? Nephrol Dial Transplant 15, 644–9.
2. Nickeleit V, Mihatsch MJ (1997) Uric acid nephropathy ande nd-stage renal disease–review of a non-disease. Nephrol Dial Transplant 12, 1832–8.
3. Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E (2011) Chronic kidney disease in gout in a managed care setting. BMC Nephrol 12, 36.
4. Johnson RJ, Kang DH, Feig D et al. (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183–90.
5. Edwards NL (2008) The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 75 (Suppl 5), S13–6.
6. Anzai N, Jutabha P, Amonpatumrat-Takahashi S, Sakurai H (2012) Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol 16, 89–95.
7. Vaziri ND, Freel RK, Hatch M (1995) Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 6, 1313–7.
8. Sánchez-Lozada LG, Tapia E, Soto V et al. (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 23, 1179–85.
9. Berger L, Yü TF (1975) Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 59, 605–13.
10. Kang DH, Nakagawa T (2005) Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 25, 43–9.
11. Weber T, Auer J, O'Rourke MF et al. (2004) Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 109, 184–9.
12. Jatoi NA, Mahmud A, Bennett K, Feely J (2009) Assessment of arterial stiffness in hypertension: comparison of oscillometric (Arteriograph), piezoelectronic (Complior) and tonometric (SphygmoCor) techniques. J Hypertens 27, 2186–91.
13. Wei W, Tölle M, Zidek W, van der Giet M (2010) Validation of the mobil-O-Graph: 24 h-blood pressure measurement device. Blood Press Monit 15, 225–8.
14. Akamatsu M, Ogawa T, Fujiu A, Matsuda N, Nitta K (2009) Clinical assessment of atherosclerotic parameters and cardiac function in chronic hemodialysis patients. Clin Exp Nephrol 13, 651–8.
15. Nelson MR, Stepanek J, Cevette M, Covalciuc M, Hurst RT, Tajik AJ (2010) Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc 85, 460–72.
16. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20, 895–900.
17. Levey AS, Coresh J, Balk E, et al. (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139, 137–47.
18. Wassertheurer S, Kropf J, Weber T et al. (2010) A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. J Hum Hypertens 24, 498–504.
19. Timio M, Venanzi S, Lolli, S et al. (1995) “Non-dipper” hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 43, 382–7.
20. Karimzadeh H, Mohtasham N, KarimifarM SM, Bonakdar ZS (2009) A case of ochronosis with gout and Monckeberg arteries. Rheumatol Int 29, 1507–10.
21. Alderman MH (2007) Podagra, uric acid, and cardiovascular disease. Circulation 116, 880–3.
22. Brook RD, Yalavarthi S, Myles JD et al. (2011) Determinants of vascular function in patients with chronic gout. J Clin Hypertens 13, 178–88.
23. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA (2010) Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 62, 170–80.
24. Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto FJ (1996) Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities. Ann Epidemiol 6, 331–40.
25. Bian S, Guo H, Ye P, Luo L, Wu H, Xiao W (2012) Serum uric Acid level and diverse impacts on regional arterial stiffness and wave reflection. Iran J Pub Health 4, 33–41.
26. Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS (2005) Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45, 28–33.
27. Perlstein TS, Gumieniak O, Williams GH et al. (2006) Uric acid and the development of hypertension: the Normative Aging Study. Hypertension 48, 1031–6.
28. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S (2001) Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24, 691–7.
29. Nacak H, van Diepen M, de Goeij MC, Rotmans JI, Dekker FW, PREPARE-2 study group (2014) Uric acid: association with rate ofrenal function decline and time until start of dialysis in incident pre-dialysis patients. BMC Nephrol 16, 91.
30. Kim IY, Lee DW, Lee SB, Kwak IS (2014) The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship. Biomed Res Int 2014, 638732.
31. Kang D, Nakagawa T, Feng L et al. (2002) A role for uric acid in renal progression. J Am Soc Nephrol 13, 2888–97.
32. Sanchez-Lozada LG, Tapia E, Avila-Casado C et al. (2002) Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283, F1105–10.
33. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez- Iturbe B (2002) Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346, 913–23.
34. López B, Salom MG, Arregui B, Valero F, Fenoy FJ (2003) Role of superoxide in modulating the renal effects of angiotensin II. Hypertension 42, 1150–6.
35. Zhang X, Liu J, Pang X, Zhao J, Wang S, Wu D (2014) Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-κB signal pathway in rat vascular smooth muscle cells. Mol Cell Endocrinol 395, 61–8.
36. Rhyu DY, Yang Y, Ha H et al. (2005) Role of reactive oxygen species in TGF-β1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 16, 667–75.
37. Yoshikawa M, Hishikawa K, Marumo T, Fujita T (2007) Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-ß1 in human renal epithelial cells. J Am Soc Nephrol 18, 58–65.
38. Schnackenberg CG (2002) Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 282, R335–42.
39. Feig DI (2009) Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 18, 526–30.
40. Akasaka H, Yoshida H, Takizawa H et al. (2014) The impact of elevation of serum uric acid level on the natural history of glomerular filtration rate (GFR) and its sex difference. Nephrol Dial Transplant 29, 1932–9.